Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Investor Presentation (April 2022)
29 slides from Aim Immunotech's investor presentation, Apr 12, 2022
Slide 1: AIM ImmunoTech
AIMIMMUNO.COM NYSE AMERICAN:AIM AIM ImmunoTech
Slide 2: Forward-Looking Statements
Forward-Looking Statements Some of the statements included in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Among other things for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private
Slide 3: Investor Highlights
Investor Highlights We are an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders Multiple oncology clinical Antiviral studies, including Only late-stage program in development programs with upcoming clin
Slide 4: Broad Oncology Pipeline Across High-Value Indications
AIM IimmunoTech Indications Ovarian Cancer (Advanced, Recurrent) Colorectal Cancer (Metastatic) Breast Cancer (Metastatic Triple-Negative) Ovarian Cancer (Advanced, Recurrent) Prostate Cancer (Early-Stage) Pancreatic Cancer Breast Cancer (Early-Stage Triple- Negative) Pancreatic Cancer Melanoma Appr
Slide 5: Extensive Viral and Immune System Disorder Pipeline
Extensive Viral and Immune System Disorder Pipeline cal Phase 1 Phase 2 Approval ee me Viral Infections COVID-19 in Cancer Patients oe Alpha-2b and Ampligen Immune System Disorder . a Approved in ' Severe CFS Single Agent eenore ME/CFS Single Agent Planning Phase 3 ’ Confirmatory Trial A Long COVID-
Slide 6: Proven Management Team
Proven Management Team Thomas K. Equels, M.LS., J.D. ) agrees nN Chief Executive Officer BIOFLORIDA MaEAW Fem (il Greenbergiraurig DREXEL UNIVERSITY Collegeof Hj|Hahnemann Medicine University HOSPITAL David R. Strayer, M.D. Chief Scientific & Medical Officer SE Peter W. Rodino III, J.D. Rodino Consu
Slide 7: Lead Program Ampligen (rintatolimod)
Lead Program Ampligen*® (rintatolimod) Significant Opportunity Across Multiple Disease Areas Generally well-tolerated with over 100,000 IV | mmun 0-O nco | ogy doses in humans Clinically tested in oncology as a single-agent therapeutic and in combination with other agents Virology Potential in oncol
Slide 8: Ampligen: Immuno-Therapy Targeting Multiple Cancers
Ampligen’ Immuno-Therapy Targeting Multiple Cancers with High-Unmet Need
Slide 9: The Critical Unmet Need in Oncology
The Critical Unmet Need in Oncology Current Therapies are Effective but Only in a Subset of Patients, Leaving Many in Need of Better Options United States Statistics Ovarian Cancer’ Pancreatic Cancer’ Breast Cancer’ 21,410 13,770 60,430 48,220 281,550 43,600 New Cases Annually Deaths Annually New Ca
Slide 10: Ampligen Induces a Wide Range of Immunologic and Anti-tumor Activities
Ampligen® Induces a Wide Range of Immunologic and Anti-tumor Activities Immuno-modulator that selectively activates TLR3 pathway r =| Exclusively activates TRIF adaptor and avoids MyD88 inflammatory pathway used by all other TLRs Promotes selective attraction of CTLs (Teff) with concomitant increase
Slide 11: Observed Complete Response in Subjects in Phase 1 Melanoma Study
Observed Complete Response in 2 of 9 Subjects in Phase 1 Melanoma Study Subject 1 Subject 2 Ampligen (300mg twice weekly) en (800mg twice weekly) ———— Complete Response + VOLUME OF RIGHT AXILLARY TUMOR MASS 9 (a zt 1S) 3 s a wo o w = = 8 S () Days on Ampligen -100 50 100 175 DAYS ON AMPLIGEN Amplige
Slide 12: Synergistic Effects in Combination with Checkpoint Inhibitor, Anti-PD-L1
Synergistic Effects in Combination with Checkpoint Inhibitor, Anti-PD-L1 Pancreatic Cancer Mouse Model Synergistic Increase in Median Survival Synergistic Increase in Time to Progression > Control > Contro! = ec 1505 = — Ampligen _ 151 \ Anti-PD-L1 E — contro! E = control 3 g E150 + Ampligen 3 180 =
Slide 13: Increase in Median Survival Combining Ampligen with Anti-PD-1
Increase in Median Survival Combining Ampligen’ with Anti-PD-1 Colorectal Carcinoma Mouse Model = Ampligen+anti-PD-1 @ anti-PD-1 i = > <= 5 a a o o 2 o o =@ control UPMC LIFE CHANGING MEDICINE 13
Slide 14: Ongoing Clinical Studies Sponsored by UPMC
Ongoing Clinical Studies Sponsored by UPMC LIFE CHANGING MEDICINE Phase 2 Advanced, Recurrent Ovarian Cancer Phase 1/2 Advanced, Recurrent Ovarian Cancer Phase 1 portion completed Enrollment and dosing ongoing Intraperitoneal chemo-immunotherapy Data published January 2022 PI: Dr. R. Edwards Cisplat
Slide 15: Ongoing Clinical Studies Sponsored by Roswell Park and Others
Ongoing Clinical Studies Sponsored by Phase 2a Stage 4 Colorectal Cancer Metastatic, Liver Study completed Chemokine modulatory regimen Data being presented at AACR April 2022 Pl: Dr. P. Boland Phase 2 Early-Stage Prostate Cancer Enrollment and dosing ongoing Aspirin and Ampligen® with or without in
Slide 16: Promising Results From Early Access Program Published in Cancers
Promising Results From Early Access Program (EAP) Published in Cancers Statistically Significant Increased Overall Survival Compared to Historical Controls in Treatment of Late-Stage Pancreatic Cancer Site: Erasmus University, The Netherlands, Eligibility: Adults with metastatic or locally conducted
Slide 17: Summary of Recent Ampligen Data Publications
AAGR ONAL. ‘American Association for Cancer Research’ gq99 cancers Summary of Recent Ampligen Data Publications Negative impact of paclitaxel on human breast tumor microenvironment and its reversal by the combination of interferon-a with TLR3 agonist rintatolimod Initial results of a phase II study
Slide 18: Ampligen: SARS-CoV-2 (COVID-19)
Ampligen’ SARS-CoV-2 (COVID-19)
Slide 19: Ampligen May Mount a Potentially Broad-Spectrum Immune System Response Against SARS-CoV-2
Ampligen’ May Mount a Potentially Broad-Spectrum Immune System Response Against SARS-CoV-2 (COVID-19) Targeting toll-like receptor 3 (TLR3) pathways, which are among the primary pathways for antiviral protection (uniquely targets TLR3 without activation of the inflammatory cytosolic helicases) Poten
Slide 20: Ongoing Phase 1/2 Study for Treatment of COVID-19 Cancer Patients
Ongoing Phase 1/2 Study for Treatment of COVID-19 Cancer Patients Actively Enrolling and Dosing Subjects Evaluating safety and effectiveness of intravenous Ampligen® to reduce replication of SARS-CoV-2 virus from upper airway in patients Next Steps: Planning intranasal study of Ampligen® to potentia
Slide 21: Ampligen: Immune System Disorders (ISD)
Ampligen’ Immune System Disorders (ISD)
Slide 22: Ampligen for the Treatment of ME/CFS
Ampligen® for the Treatment of ME/CFS Only late-stage program in development in the U.S. for the treatment of ME/CFS, with an approval in Argentina Developing protocol for confirmatory Phase 3 trial, required for U.S. NDA Toll-Like Receptor 3 agonist which activates the innate immune system and indu
Slide 23: COVID-Induced Chronic Fatigue (Long COVID)
Fatigue | Brain Fog COVID-Induced Chronic Fatigue (Long COVID or ‘Long Haulers’) Amended ongoing open-label AMP-511 study in ME/CFS to include up to 20 long COVID subjects Currently treating long COVID subjects Salm ImmunoTech Chronic Illness Following COVID-19 Chronic illness following recovery is
Slide 24: Corporate Overview
Corporate Overview
Slide 25: Intellectual Property Portfolio - Market Exclusivity
Intellectual Property Portfolio - Market Exclusivity 44 39 Patents Worldwide Pending Applications Orphan Drug Designation (FDA and EMA): Ampligen® Indications: 7 years market exclusivity following FDA U.S. — Pancreatic Cancer, Melanoma, approval ME/CFS, Renal Cell Carcinoma, AIDS 10 years market exc
Slide 26: Financial Snapshot
Financial Snapshot NYSE American: AIM Sufficient Capital to Fund Operations Through Multiple Key Clinical Milestones ImmunoTec! 48M Shares Outstanding
Slide 27: Upcoming 2022 Milestones
Upcoming 2022 Milestones Q1 2022 | Q2 2022 | Q3 2022 | 04 2022 Oncology Oncology Immune System Disorders V January 2022: Advanced Recurrent * Pancreatic Caneet Expressing! ERS * Report Interim Results from AMP- R " “ae Receptors: Publication of Preclinical 511 COVID19 and Progress from Ovarian Cance
Slide 28: Investment Summary
Investment Summary Immuno-Pharma Company with Broad Pipeline Across Multiple High-Value Indications in Oncology, Virology and Immune-Deficiency Lead program Ampligen® has Leveraging external Growing body of data favorable safety profile and collaborators to fund potentially supports promising effica
Slide 29: AIMIMMUNO.COM
AIMIMMUNO.COM NYSE AMERICAN:AIM